Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/32097760 below:

Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries

Affiliations

• ¹ OPEN, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark.
• ² Novartis Healthcare Pvt. Ltd., Hyderabad, India.
• ³ Novartis Pharma AG, Basel, Switzerland.
• ⁴ Department of Endocrinology, Rikshospitalet and University of Oslo, Oslo, Norway.
• ⁵ Centre for Pharmacoepidemiology, Clinical Epidemiology Unit, Karolinska Institutet Stockholm, Sweden; Department of Drug Design and Pharmacology, University of Copenhagen, Denmark.
• ⁶ OPEN, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark; Department of Medicine, Holbæk, Hospital, Denmark. Electronic address: b.abrahamsen@physician.dk.

• PMID: 32097760
• DOI: 10.1016/j.bone.2020.115296

Item in Clipboard

Katrine Hass Rubin et al. Bone. 2020 May.

• ¹ OPEN, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark.
• ² Novartis Healthcare Pvt. Ltd., Hyderabad, India.
• ³ Novartis Pharma AG, Basel, Switzerland.
• ⁴ Department of Endocrinology, Rikshospitalet and University of Oslo, Oslo, Norway.
• ⁵ Centre for Pharmacoepidemiology, Clinical Epidemiology Unit, Karolinska Institutet Stockholm, Sweden; Department of Drug Design and Pharmacology, University of Copenhagen, Denmark.
• ⁶ OPEN, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark; Department of Medicine, Holbæk, Hospital, Denmark. Electronic address: b.abrahamsen@physician.dk.

• PMID: 32097760
• DOI: 10.1016/j.bone.2020.115296

Item in Clipboard

Background: This observational safety study used national registers to compare the real world cardiovascular and skeletal safety of zoledronic acid (ZA) against oral bisphosphonates (oBP) and untreated population controls.

Methods: Propensity score matched cohort study in Sweden and Denmark.

Results: Matched cohort 1 included 8739 ZA users and 25,577 oBP users while matched cohort 2 included 8731 ZA users and 25,924 untreated subjects. In comparison to oBP users, heart failure risk was higher in ZA users, with an adjusted HR (adj) (95%CI) of 1.17 (1.04;1.32) and a higher all-cause mortality (adj HR 1.24 (1.15; 1.34)), however, there was no increased risk of cardiovascular mortality. In the comparison to untreated subjects, ZA users showed a higher risk of atrial fibrillation, adj HR 1.18 (1.05;1.32), arrhythmias adj HR 1.18 (1.06;1.31), and heart failure, adj HR 1.38 (1.24;1.54). Cardiovascular mortality was lower in ZA users (adj HR 0.87 (0.77; 0.98)) and risk of adverse skeletal outcomes was significantly higher, reflecting more severe osteoporosis in these patients. There was no association of cardiovascular risk with increasing exposure time. Sensitivity analyses produced similar findings with no substantial changes in event rates.

Conclusions: We noted an increased risk of heart failure, fractures and death among ZA users compared with oral BP. The risk of cardiovascular and skeletal outcomes was higher in ZA users than in matched population controls, but there was no increase in cardiovascular mortality in ZA users compared to oral BP or untreated controls. Despite propensity score matching, it is not possible to determine with certainty whether the increased risk of cardiovascular outcomes is consistent with a true drug effect or higher baseline risk in patients who begin ZA treatment.

Keywords: Cardiovascular risk; Matched cohorts; Observational cohort study; Propensity score; Skeletal risk; Zoledronic acid.

Copyright © 2020 Elsevier Inc. All rights reserved.

PubMed Disclaimer

• Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density.

  Rodríguez AJ, Ernst MT, Nybo M, Prieto-Alhambra D, Ebeling PR, Hermann AP, Abrahamsen B. Rodríguez AJ, et al. J Clin Endocrinol Metab. 2020 Oct 1;105(10):dgaa481. doi: 10.1210/clinem/dgaa481. J Clin Endocrinol Metab. 2020. PMID: 32717068

• Zoledronic acid for hip fracture during initial hospitalization.

  Fan W, Sun X, Leder BZ, Lee H, Ly TV, Pu CT, Franco-Garcia E, Bolster MB. Fan W, et al. J Bone Miner Res. 2024 Aug 21;39(8):1061-1070. doi: 10.1093/jbmr/zjae101. J Bone Miner Res. 2024. PMID: 38952014

• Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score-Matched Cohort Study.

  D'Silva KM, Cromer SJ, Yu EW, Fischer M, Kim SC. D'Silva KM, et al. J Bone Miner Res. 2021 Jan;36(1):52-60. doi: 10.1002/jbmr.4174. Epub 2020 Nov 2. J Bone Miner Res. 2021. PMID: 33137852 Free PMC article.

• Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.

  Folkestad L. Folkestad L. Dan Med J. 2018 Apr;65(4):B5454. Dan Med J. 2018. PMID: 29619932 Review.

• Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.

  John Camm A. John Camm A. Clin Ther. 2010 Mar;32(3):426-36. doi: 10.1016/j.clinthera.2010.03.014. Clin Ther. 2010. PMID: 20399982 Review.

• Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS).

  Su S, Wu L, Zhou G, Peng L, Zhao H, Wang X, Li K. Su S, et al. Front Pharmacol. 2023 Nov 1;14:1225919. doi: 10.3389/fphar.2023.1225919. eCollection 2023. Front Pharmacol. 2023. PMID: 38027014 Free PMC article.

• Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies.

  Rodríguez AJ, Abrahamsen B. Rodríguez AJ, et al. JBMR Plus. 2021 Jun 23;5(7):e10522. doi: 10.1002/jbm4.10522. eCollection 2021 Jul. JBMR Plus. 2021. PMID: 34258509 Free PMC article. Review.

• Insights and implications of sexual dimorphism in osteoporosis.

  Zhang YY, Xie N, Sun XD, Nice EC, Liou YC, Huang C, Zhu H, Shen Z. Zhang YY, et al. Bone Res. 2024 Feb 18;12(1):8. doi: 10.1038/s41413-023-00306-4. Bone Res. 2024. PMID: 38368422 Free PMC article. Review.

• Association between bisphosphonate use and stroke risk: a meta-analysis.

  Lin SM, Lin JY, Tu YK, Wu CH, Peng CC, Munir KM, Bukhari K, Jaggon K, Fu Y, Loh CH, Huang HK. Lin SM, et al. Osteoporos Int. 2023 Sep;34(9):1625-1636. doi: 10.1007/s00198-023-06781-z. Epub 2023 May 30. Osteoporos Int. 2023. PMID: 37249610

• Beyond the Bone Health: A Narrative Review Unveiling the Role of Bisphosphonates in Reducing the Risk of Myocardial Infarction.

  Tabasum P, Umar M, Richard RM, Khan S, Momna F, Shahwar DE, Hidayat A, Nashwan AJ, Sajjad W, Mohamed WI. Tabasum P, et al. Cureus. 2025 Mar 5;17(3):e80089. doi: 10.7759/cureus.80089. eCollection 2025 Mar. Cureus. 2025. PMID: 40190923 Free PMC article. Review.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3